Robert Zeiser News Today

The expert panel explores the approval of ruxolitinib for chronic GVHD based on the REACH3 trial. The panel highlights the trial’s outcomes, long-term follow-up data, and the evolving shift in clinical practices.

The three-year final analysis of efficacy and safety of the REACH3 trial showed that patients with steroid-refractory or dependent chronic graft-versus-host disease benefited more with Jakafi compared with the best available treatment.

Treatment with ruxolitinib led to prolonged failure-free survival and improved disease control vs best available treatment in patients with either steroid-refractory or -dependent chronic graft-vs-host disease.

02.06.2022 - – Interim proof-of-concept data anticipated from STARGAZE in H1 2023 – First-in-class regenerative, non-immunosuppressive approach to treating acute Graft-versus-Host Disease – Second clinical indication under evaluation for apraglutide, ... Seite 1

Jakavi treats a potentially life-threatening condition which often effects transplant patients - News - PharmaTimes

Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis receives positive CHMP opinion for Jakavi® to treat acute and chronic graft-versus-host disease

CHMP opinion based on Phase III REACH2 and REACH3 trials that showed Jakavi improved response rates and failure-free survival compared to best available therapy1,2 Graft-versus-host disease (GvHD)

CHMP opinion based on Phase III REACH2 and REACH3 trials that showed Jakavi improved response rates and failure-free survival compared to best available therapy1,2 Graft-versus-host disease is a... | March 25, 2022

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) is establishing eleven new Collaborative Research Centers (CRC) to promote world-class research at universities. This was announced by the relevant Grants Committee, which met by video conference due to the coronavirus pandemic.